Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Vertex Pharmaceuticals (VRTX) through the VizualStocks API.
Net revenue from Vertex's established cystic fibrosis medicines KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI. It excludes TRIKAFTA/KAFTRIO and the newer ALYFTREK therapy, which Vertex reports separately.
otherCysticFibrosisProductRevenueNon-product revenue Vertex reports separately from medicine sales, such as collaboration or licensing payments recognized under partner agreements. It is not a catch-all for newer products; ALYFTREK, CASGEVY and JOURNAVX are separate product-revenue lines in Vertex's disclosures.
otherRevenueNet product revenue from Vertex's triple-combination cystic fibrosis therapy sold as TRIKAFTA in the United States and certain other markets and as KAFTRIO in many international markets. The two brand names represent the same core therapy and together remain Vertex's largest product franchise.
trikaftaKaftrioRevenue